Treatment of clinical stage I non-seminoma
Open Access
- 1 April 2021
- journal article
- review article
- Published by Elsevier in Asian Journal of Urology
- Vol. 8 (2) , 161-169
Abstract
No abstract availableKeywords
This publication has 59 references indexed in Scilit:
- Global incidence and outcome of testicular cancerClinical Epidemiology, 2013
- Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side EffectsCancers, 2011
- Long-term follow-up after risk-adapted treatment in clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT) implementing adjuvant CVB chemotherapy. A SWENOTECA studyAnnals of Oncology, 2010
- Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacyAnnals of Oncology, 2009
- Chemotherapy in Patients with Teratoma with Malignant TransformationEuropean Urology, 2007
- Long-Term Results of Laparoscopic Retroperitoneal Lymph-Node Dissection for Clinical Stage I Nonseminomatous Germ-Cell Testicular CancerJournal of Endourology, 2007
- Hearing Genes and Cisplatin Deafness: A Pilot StudyThe Laryngoscope, 2006
- Modified retroperitoneal lymphadenectomyBJU International, 2004
- Bleomycin-induced pulmonary toxicity in chemotherapy for testicular cancerExpert Opinion on Drug Safety, 2003
- Immediate Adjuvant Chemotherapy versus Observation with Treatment at Relapse in Pathological Stage II Testicular CancerNew England Journal of Medicine, 1987